Cardio Diagnostics Wins “Clinical Diagnostics Solution of the Year” Award From BioTech Breakthrough
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry
CHICAGO, October 27, 2021 – Cardio Diagnostics, Inc., a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, today announced it has been selected as the winner of the “Clinical Diagnostics Solution of the Year” award in the inaugural Biotech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
Cardio Diagnostics’ patent-pending, evidence-based core technology combines artificial intelligence (AI) and the testing of two types of DNA biomarkers, genetics and epigenetics. Genetic biomarkers represent an individual’s inherited risk, while their epigenetic biomarkers represent acquired risk influenced by lifestyle and environment.
Cardio Diagnostics’ technology consists of two parts. The first involves the use of their proprietary laboratory testing assays to profile the DNA biomarkers. The second involves aggregating these biomarkers using their proprietary AI algorithms to derive personalized insights to better prevent and detect heart disease. This is the first integrated genetic-epigenetic-based technology in the world for heart disease and is being incorporated into a series of products for various indications such as coronary heart disease (CHD), stroke, diabetes, and heart failure.
Cardio Diagnostics launched its first clinical product, Epi+Gen CHD™, earlier this year. It is a clinical CHD risk assessment test that combines the laboratory profiling of five genetic and three DNA methylation (epigenetic) biomarkers with artificial intelligence-driven interpretation of these biomarkers. This is the only clinical test that assesses near-term risk for CHD – assessing an individual’s likelihood of having a CHD-related event such as a heart attack in the next three years.
Furthermore, Epi+Gen CHD, being a 100% remote test via telemedicine and at-home sampling, is a more accessible, personalized, and precise clinical test for the primary prevention of CHD than the older lipid-based tests.
“We are simultaneously humbled and thrilled to be recognized by BioTech Breakthrough. We believe that prevention and early detection should be the norm and that epigenetics-based technologies driven by AI will usher in a new era of Precision Cardiovascular Medicine,” said Meesha Dogan Ph.D., Chief Executive Officer and Co-Founder of Cardio Diagnostics. “Effective clinical decisions that include personalization of interventions to improve patient outcomes hinge on highly precise and advanced diagnostics tools. We will continue to lead this change through our technologies to enable better health outcomes.”
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top technology companies, solutions, and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,200 nominations from over 12 different countries throughout the world.
“CHD is the most common type of heart disease and the major cause of heart attacks. In the case of risk assessment for a heart attack, the decision is tied to understanding a patient’s risk profile so a data-driven tailored plan can be made to help the patient before it is too late,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “Epi+Gen CHD is a breakthrough product in the biotech market. This technology from Cardio Diagnostics is not just about doubling test sensitivity, but it’s also bridging the gender gap that is currently present with the gold standard approach. Congratulations on being the winner of our ‘Clinical Diagnostics Solution of the Year’ award.”
About Cardio Diagnostics, Inc.
Cardio Diagnostics is a biotechnology company that is making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company’s vision is to transform medical care for cardiovascular disease from reactive to proactive. With prevention and early detection as the new norm, epigenetics-based technologies driven by artificial intelligence will usher in an era of Precision Cardiovascular Medicine. Developed in partnership with a team of dedicated scientists and clinicians, the Cardio Diagnostics’ Epi+Gen CHD™ test helps clinicians better assess each patient’s unique risk profile for disease. For more information, see www.cardiodiagnosticsinc.com
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services, and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com